JPMorgan lowered the firm’s price target on Adaptive Biotechnologies to $11 from $12 and keeps an Overweight rating on the shares post the Q3 report. The analyst acknowledges the “noisy quarter” but remains encouraged by the continued progress on ClonoSeq.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ADPT:
- Adaptive Biotechnologies sees 2023 MRD business revenue $100M-$105M
- Adaptive Biotechnologies reports Q3 EPS (35c), consensus (34c)
- Adaptive Biotechnologies announces new collaboration with BeiGene
- Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline
- Adaptive Biotechnologies price target lowered to $10 from $13 at Morgan Stanley
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue